The 2026 Healthtech Messaging Index

Rank#211of 302

Formation Bio

formation.bio·scored November 1, 2026

42out of 100

16/38

Invisible

The page is doing some work, but the story isn't landing fast enough. Buyers and AI are both left guessing what makes Formation Bio different.

InvisibleAI recommends them? No
Formation Bio homepage

The page we scored

The AI Recommendation Check

When we asked AI who to recommend for AI-native drug development company / clinical-stage asset licensing and development platform, it named:

Buyer we put in the prompt: Business Development or Licensing executive at a pharma company, biotech, or university technology transfer office looking to out-license or co-develop clinical-stage drug assets. Both the buyer and the category were inferred from Formation Bio’s homepage alone. The model had no web access.

Recursion PharmaceuticalsInsilico MedicineExscientiaAbsciBenevolentAIRelay TherapeuticsIktosSchrodinger

Formation Bio was not on the list.

A buyer who asked AI this question got 8 names and moved on. Formation Bio never came up.

We asked AI who it recommends for "Business Development or Licensing executive at a pharma company, biotech, or university technology transfer office looking to out-license or co-develop clinical-stage drug assets" looking for "AI-native drug development company / clinical-stage asset licensing and development platform". It named Recursion Pharmaceuticals, Insilico Medicine, Exscientia, Absci, BenevolentAI. You did not appear. AI can't recommend what it can't clearly understand.

Overall assessment

Formation Bio's biggest strength is solution clarity ... one mid-page paragraph cleanly explains the acquisition-plus-development model in a repeatable sentence. The biggest gap is trust infrastructure: there are no named partners, no customer testimonials, no before/after metrics, and no cost-of-inaction framing, which means the page reads like a vision statement rather than a credible business case for a potential licensing partner.

Signal by category

Narrative Clarity

8 signals

8/16

Trust Signal

4 signals

2/8

AI Signal

6 signals

5/12

Conversion Signal

1 signal

1/2
0

Weakest signal · fix this first

07Cost of Inaction

“No mention of cost of inaction, missed milestones, lost competitive position, or financial stakes for doing nothing.”

The page never names what a pharma partner or patient loses by not acting ... no urgency, no stakes, no price of the status quo.

All 19 signals, scored 0 to 2.

Narrative Clarity

8 signals

8/16
  • 01The 7-Second Test

    “The pharma company of the future. Our mission is to bring new treatments to patients faster and more efficiently.”

    The problem (slow drug development) and mission are discernible in seconds, but who this is 'for' (pharma companies with clinical-stage assets to license) is completely absent above the fold, and there is no clear point of view stated upfront.

    1
  • 02Rebellion / Movement

    “The drug development bottleneck... The existing drug development ecosystem can't keep up with the pace of scientific discovery.”

    There is a named structural enemy (the drug development bottleneck and a broken ecosystem), but it is buried mid-page and never given a punchy, ownable name or rallying cry that functions as a movement.

    1
  • 03Owned Language & Category

    “tech-driven, AI-native pharma company" and "radical efficiency throughout the drug development lifecycle”

    Phrases like 'AI-native' and 'radical efficiency' hint at a distinctive frame but are not coined terms or owned categories an LLM would exclusively attribute to Formation Bio.

    1
  • 04ICP Clarity

    “Formation Bio acquires clinical-stage drugs from pharma, universities, and biotech”

    The page eventually names the source of assets (pharma, universities, biotech) but never explicitly addresses a specific buyer persona by role, company size, or stage, so ICP clarity is partial at best.

    1
  • 05Problem Leadership

    “drug development costs have exponentially increased, creating a widening gap between the backlog of known potential treatments”

    The problem is named and framed reasonably well but it is introduced mid-page, not in the hero, so the page leads with the company's identity rather than the buyer's pain.

    1
  • 06Solution Clarity

    “Formation Bio acquires clinical-stage drugs from pharma, universities, and biotech and develops them faster and more efficiently by leveraging our proprietary tech-driven drug development platform.”

    This single sentence clearly explains what the company does and a visitor could repeat it accurately after reading it.

    2
  • 07Cost of Inactionweakest

    “No mention of cost of inaction, missed milestones, lost competitive position, or financial stakes for doing nothing.”

    The page never names what a pharma partner or patient loses by not acting ... no urgency, no stakes, no price of the status quo.

    0
  • 08Promised Land

    “reaching inflection points earlier than industry norms while also accelerating access to new potential treatments for patients”

    An 'after' state is implied (faster inflection points, more patients reached) but it is vague and not painted as a vivid, specific promised land with concrete outcomes.

    1

Trust Signal

4 signals

2/8
  • 09Proof & Evidence

    “Our team and advisors have collectively worked on 45+ approved drugs”

    The single number (45+ approved drugs) is the only concrete data point; there are no before/after deltas, timeline comparisons, cost savings, or named program outcomes.

    1
  • 10Social Proof

    “No customer logos, named testimonials, case studies, or partner quotes anywhere on the page.”

    There is zero social proof ... no partner names, no quotes with names and titles, no referenced deals beyond the $600M fund announcement headline.

    0
  • 11Authority & Credibility

    “Our team and advisors have collectively worked on 45+ approved drugs" and the $600M fund announcement”

    The 45+ approved drugs stat and the fund size signal credibility but no founders are named, no frameworks are cited, and no original research is referenced on this page.

    1
  • 12Alternatives Acknowledged

    “No mention of competitors, alternative approaches, CROs, or the 'do nothing' option anywhere on the page.”

    The page completely ignores the buyer's alternatives and never acknowledges what they might do instead of partnering with Formation Bio.

    0

AI Signal

6 signals

5/12
  • 13Customer Focus

    “striving to meet critical unmet patient need" alongside "enables us and our partners to realize greater value per drug program”

    The page oscillates between the patient as beneficiary and the company as protagonist; the partner/buyer's transformation is secondary to Formation Bio's own narrative.

    1
  • 14AI-Parmesan Index

    “tech-driven, AI-native pharma company" and "proprietary tech-driven, AI-native platform”

    'AI-native' is repeated as a label but the page provides no mechanistic explanation of how AI is applied, what it does differently, or what outputs it produces, making it closer to AI-Parmesan than substance.

    1
  • 15LLM Quotability

    “Formation Bio acquires clinical-stage drugs from pharma, universities, and biotech and develops them faster and more efficiently by leveraging our proprietary tech-driven drug development platform.”

    This sentence is clean and declarative enough to be cited, but it lacks specificity (no metrics, no named mechanism) that would make it a high-confidence LLM recommendation.

    1
  • 16Copyright Freshness

    “Introducing the $600M Formation Bio Drug Development Accelerator Fund" (no date visible; no copyright year in scraped content)”

    The fund announcement suggests recency but no visible dates on blog posts, case studies, or a copyright year are present in the scraped content, leaving recency signals weak.

    1
  • 17Entity Distinctiveness

    “We acquire and develop clinical-stage assets through flexible structures and financing pathways" combined with "AI-native pharma company”

    The combination of in-house AI platform plus asset acquisition from pharma/biotech is somewhat distinctive, but the generic language ('AI-native,' 'best-in-class') means a competitor could swap their logo in with minimal edits.

    1
  • 18AI Recommendation Check

    “AI's picks: Recursion Pharmaceuticals, Insilico Medicine, Exscientia, Absci, BenevolentAI, Relay Therapeutics. You were not named.”

    We asked AI who it recommends for "Business Development or Licensing executive at a pharma company, biotech, or university technology transfer office looking to out-license or co-develop clinical-stage drug assets" looking for "AI-native drug development company / clinical-stage asset licensing and development platform". It named Recursion Pharmaceuticals, Insilico Medicine, Exscientia, Absci, BenevolentAI. You did not appear. AI can't recommend what it can't clearly understand.

    0

Conversion Signal

1 signal

1/2
  • 19Path & CTA Clarity

    “Contact Us" CTA and "Partner With Us" section exist, but no numbered process or soft secondary CTA is present.”

    There is one CTA ('Contact Us') and a vague soft prompt ('Partner With Us') but no visible numbered steps or clear process path connecting them, so conversion architecture is incomplete.

    1

Your move

Think Formation Bio’s score is wrong? Good. Let’s look at it together.

Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Formation Bio the AI recommendation, and what to write instead.

Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.

← Back to the full Healthtech index

We revamp websites that ChatGPT ignores.

See the 90-Day AI Website Rebuild →